Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-Current Assets for 10 consecutive years, with $13.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 26.52% to $13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.8 million through Dec 2025, down 38.2% year-over-year, with the annual reading at $13.3 million for FY2025, 26.52% down from the prior year.
  • Non-Current Assets for Q4 2025 was $13.3 million at Rhythm Pharmaceuticals, up from $12.1 million in the prior quarter.
  • The five-year high for Non-Current Assets was $31.4 million in Q1 2022, with the low at $9.9 million in Q2 2021.
  • Average Non-Current Assets over 5 years is $21.2 million, with a median of $23.1 million recorded in 2024.
  • The sharpest move saw Non-Current Assets skyrocketed 262.88% in 2021, then plummeted 50.76% in 2025.
  • Over 5 years, Non-Current Assets stood at $21.1 million in 2021, then skyrocketed by 33.63% to $28.2 million in 2022, then dropped by 13.34% to $24.5 million in 2023, then decreased by 26.16% to $18.1 million in 2024, then dropped by 26.52% to $13.3 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $13.3 million, $12.1 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.